• Aliases: TCN-PM; VD-0002; NSC-154020
    • An orally available synthetic tricyclic nucleoside that inhibits the phosphorylation, activation, and signaling of AKT-1, -2, and -3
    • Currently under investigation in phase 1 clinical trials with solid tumors; phase 1/2 in metastatic breast cancer
    • Recommended phase 2 dose: 20 mg/m2 continuous intravenous infusion (c.i.v) over 5 days every 6 weeks
    • Side effects: Nausea/vomiting, hyperglycemia, severe fatigue, hepatotoxicity, thrombocytopenia, anorexia
    (Garrett et al., 2011)
    Other topics in Targeted and Immunotherapy Agents